Patents Assigned to Takeda Phamaceutical Company Limited
  • Publication number: 20200392445
    Abstract: Provided is a cell suspension culturing apparatus suitable for large-scale culture of cells, the cell culturing apparatus comprising a culture solution aspirator having a double-tube structure comprising an outer tube and an inner tube inserted in a lumen of the outer tube, and a suspension culture vessel, wherein in the culture solution aspirator, the outer tube comprises a filter through which a culture solution is passed, the inner tube comprises a suction port for the culture solution passed through the filter, and an air hole which communicates the lumen of the outer tube with the outside is disposed distally in a direction of insertion of the outer tube into the suspension culture vessel.
    Type: Application
    Filed: December 21, 2018
    Publication date: December 17, 2020
    Applicants: Kyoto University, Takeda Phamaceutical Company Limited
    Inventors: Junji YAMAURA, Shinobu KUWAE, Taro TOYODA, Shuhei KONAGAYA
  • Publication number: 20170044143
    Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. (I) wherein each symbol is as described in the specification, or a salt thereof.
    Type: Application
    Filed: April 22, 2015
    Publication date: February 16, 2017
    Applicant: Takeda Phamaceutical Company Limited
    Inventors: Masami YAMADA, Shinkichi SUZUKI, Takahiro SUGIMOTO, Minoru NAKAMURA, Hiroki SAKAMOTO, Makoto KAMATA
  • Patent number: 9346829
    Abstract: The present invention provides a method of treating nicotine addiction comprising administering a 5-HT3 receptor antagonists of Formula (I):
    Type: Grant
    Filed: March 12, 2015
    Date of Patent: May 24, 2016
    Assignee: Takeda Phamaceutical Company Limited
    Inventors: Stephen Hitchcock, Holger Monenschein, Holly Reichard, Huikai Sun, Shota Kikuchi, Todd Macklin, Maria Hopkins
  • Patent number: 9187497
    Abstract: Disclosed are compounds of the following formula: in which R1, R2, R5, R6, R7, R31, u, and X are defined in the specification. Also disclosed are pharmaceutical compositions, kits, and articles of manufacture, which contain the compounds, methods and intermediates useful for making the compounds, and methods of using the compounds to treat diseases, disorders, and conditions related to PARP activity.
    Type: Grant
    Filed: August 1, 2014
    Date of Patent: November 17, 2015
    Assignee: Takeda Phamaceutical Company Limited
    Inventors: Anthony R. Gangloff, Andrew John Jennings, Benjamin Jones, Andre A. Kiryanov
  • Publication number: 20130245031
    Abstract: Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein G, L1, L2, R1, R2, R3, and R4 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, pharmaceutical compositions containing them, and their use for treating disorders, diseases, and conditions involving the immune system and inflammation, including rheumatoid arthritis, hematological malignancies, epithelial cancers (i.e., carcinomas), and other disorders, diseases, and conditions for which inhibition of SYK is indicated.
    Type: Application
    Filed: May 2, 2013
    Publication date: September 19, 2013
    Applicant: Takeda Phamaceutical Company Limited
    Inventors: Yasuyoshi Arikawa, Benjamin Jones, Betty Lam, Christopher Smith, Massashi Takahashi, Qing Dong, Victoria Feher, Zhi Nie
  • Patent number: 8183212
    Abstract: The present invention provides a compound represented by the following formula (1); wherein R1 is an aryl group etc.; R2 is —CO—NH— etc.; R3 is a methyl group having an aromatic group or a cycloalkyl group; R4 is a hydrogen atom etc.; R5 is a methyl group having an aromatic group; and R6 is an amino group or an N-alkyl substituted amino group, having a low-molecular weight and a superior GPR54 agonist activity, and a pharmaceutical composition containing the compound.
    Type: Grant
    Filed: October 24, 2006
    Date of Patent: May 22, 2012
    Assignees: Kyoto University, Takeda Phamaceutical Company Limited
    Inventors: Nobutaka Fujii, Shinya Oishi, Kenji Tomita, Ayumu Niida
  • Publication number: 20090326229
    Abstract: To provide methods for preparing alpha-carboline derivatives in few steps, as well as conveniently and industrially advantageously.
    Type: Application
    Filed: August 2, 2007
    Publication date: December 31, 2009
    Applicant: Takeda Phamaceutical Company Limited
    Inventors: Masahiro Mizuno, Hideya Mizufune, Misayo Sera, Masahiro Mineno, Tsuyoshi Ueda
  • Patent number: 7476657
    Abstract: This invention provides compounds including peptides and peptidomimetics that can be used to treat cell proliferative disorders, such as those associated with benign and malignant tumor cells. While the invention is not limited to any particular mechanism, the compounds of the invention appear to function at least in part by inhibiting G2 cell cycle checkpoint. Thus, invention compounds can be used to inhibit cell growth alone or be used in combination with a nucleic acid damaging treatment to inhibit cell growth.
    Type: Grant
    Filed: September 6, 2005
    Date of Patent: January 13, 2009
    Assignee: Takeda Phamaceutical Company Limited
    Inventors: Takumi Kawabe, Hidetaka Kobayashi